Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 clinical trial of NEOK 001

Next Previous
Trial Profile

A Phase 1 clinical trial of NEOK 001

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NEOK 001 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 21 Jan 2026 According to a NEOK Bio media release, the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for NEOK001, enabling initiation of a Phase 1 clinical trial. Company plans to initiate a Phase 1 clinical study by 1H2026, dosing the first patient expected in the coming months.
  • 01 Dec 2025 New trial record
  • 04 Nov 2025 NEOK plans to file an Investigational New Drug (IND) application by early 2026 and initiate Phase 1 clinical trial in mid-2026 in the U.S. First data readouts is expected in 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top